Negotiable: Oxford Nanopore Technologies: The Bioinformatics Quality Assurance Specialist in the Customer Workflows Group will ensure the accuracy, reliability, and compliance of bioinformatics software and data. Oxford, England

Negotiable: Oxford Nanopore Technologies: We are looking for a Sample Technologies Manager to join our RNA/cDNA Sample Technologies team. Oxford, England

Acrivon Therapeutics: Acrivon is a clinical stage biopharmaceutical company developing precision oncology medicines that it matches to patients whose tumors are predicte... Watertown, Massachusetts

Notice NOT-NS-24-106 from the NIH Guide for Grants and Contracts

Notice NOT-CA-24-065 from the NIH Guide for Grants and Contracts

Notice NOT-CA-24-067 from the NIH Guide for Grants and Contracts

Funding Opportunity PAR-24-229 from the NIH Guide for Grants and Contracts. (Reissue of PAR-18-486, PAR-21-153) The purpose of the NINDS Faculty Development Award to Promote Diversity in Neuroscience Research (K01) is to diversify the pool of independent neuroscience research investigators by providing junior faculty with research cost support, protected research time and career stage appropriate professional development mentorship in neuroscience research. Individuals from backgrounds underrepresented in biomedical research are eligible for support under this award if they have doctoral research degrees (Ph.D. or equivalent) and are in the first 3 years of a faculty tenure track or equivalent position at the time of application. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary study to an existing trial, as part of their research and career development. NINDS will only accept applications to this FOA that propose human mechanistic trials/studies that meet NIH's definition of a clinical trial and that fall within the NINDS research priorities. Applicants are strongly advised to consult with NINDS program staff prior to submitting an application with human subjects to determine the appropriate funding opportunity.

Funding Opportunity PAR-24-228 from the NIH Guide for Grants and Contracts. (Reissue of PAR-18-490, PAR-21-234) The purpose of the NINDS Faculty Development Award to Promote Diversity in Neuroscience Research (K01) is to diversify the pool of independent neuroscience research investigators by providing junior faculty with research cost support, protected research time and career stage appropriate professional development mentorship in neuroscience research. Individuals from backgrounds underrepresented in biomedical research are eligible for support under this award if they have doctoral research degrees (Ph.D. or equivalent) and are in the first 3 years of a faculty tenure track or equivalent position at the time of application. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary study to a clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor.

Notice NOT-TR-24-028 from the NIH Guide for Grants and Contracts

Notice NOT-OD-24-146 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-NS-24-040 from the NIH Guide for Grants and Contracts. Reissue of RFA-NS-19-038. This Notice of Funding Opportunity (NOFO) invites applications to support the National Institute of Neurological Disorders and Stroke (NINDS) Human Cell and Data Repository (NHCDR). The repository will maintain the current collection of fibroblast and induced pluripotent stem cell (iPSC) lines as well as develop, characterize, expand source cells and iPSCs, and where appropriate, genetically modify new high-quality iPSC lines accordance with the NINDS mission. The NINDS Human Cell and Data Repository will distribute human cell resources broadly to qualified academic and industry researchers to advance basic and translational research in neurological disorders.

Funding Opportunity PAR-24-212 from the NIH Guide for Grants and Contracts. The purpose of the NINDS Alzheimers Disease and Alzheimers Disease-Related Dementias (AD/ADRD) Advanced Postdoctoral Career Transition Award to Promote Diversity (K99/R00) program is to support of a cohort of new and talented, independent investigators from diverse backgrounds conducting AD/ADRD research. The program is designed to facilitate a timely transition of promising postdoctoral researchers from diverse backgrounds (e.g., see NIHs Interest in Diversity) from their mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions. The program will provide independent NIH research support during this transition in order to help awardees establish independent research programs in the AD/ADRD field.This FOA is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary study to a clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor.

Funding Opportunity PAR-24-213 from the NIH Guide for Grants and Contracts. The purpose of the NINDS Alzheimers Disease and Alzheimers Disease-Related Dementias (AD/ADRD) Advanced Postdoctoral Career Transition Award to Promote Diversity (K99/R00) program is to support of a cohort of new and talented, independent investigators from diverse backgrounds conducting AD/ADRD research. The program is designed to facilitate a timely transition of promising postdoctoral researchers from diverse backgrounds (e.g., see NIHs Interest in Diversity) from their mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions. The program will provide independent NIH research support during this transition in order to help awardees establish independent research programs in the AD/ADRD field.This FOA is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary study to a clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor.

Notice NOT-OD-24-144 from the NIH Guide for Grants and Contracts

Acrivon Therapeutics: Acrivon is a clinical stage biopharmaceutical company developing precision oncology medicines that it matches to patients whose tumors are predicte... Watertown, Massachusetts

The George Washington University: I. JOB OVERVIEW Job Description Summary: Founded in 1824, the GW School of Medicine and Health Sciences (SMHS) is the 11th oldest medical school in... Washington, Washington DC

Funding Opportunity PAR-24-222 from the NIH Guide for Grants and Contracts. Some projects initiated with SBIR or STTR funding require considerable financing beyond the SBIR/STTR Phase II award to achieve commercialization. The development of medical biotechnology products is often impeded by a significant funding gap (known as the Valley of Death) between the end of the SBIR/STTR Phase II award and the commercialization stage. The goal of this FOA is to assist applicants in pursuing the next appropriate milestone(s) necessary to advance a product/technology that requires Federal regulatory approval or to bring a complex research tool to market. This opportunity aims to facilitate the transition of previously funded SBIR and STTR Phase II projects to the commercialization stage by promoting partnerships between NINDS SBIR or STTR awardees and third-party investors and/or strategic partners in the Phase IIB competing renewal. Applicants are strongly encouraged to secure independent third-party funding throughout the Phase IIB project period.

Funding Opportunity PAR-24-221 from the NIH Guide for Grants and Contracts. (Reissue of PAR-18-665) This Funding Opportunity Announcement (FOA) encourages Small Business Innovation Research (SBIR) applications from small business concerns (SBCs) that seek additional funding to support clinical trials for projects that were previously funded by NIH SBIR and STTR Phase II awards. The projects must focus on products related to the mission and goals of the National Institute of Neurological Disorders and Stroke (NINDS) and may evaluate drugs, biologics, devices, or diagnostics, as well as surgical, behavioral or rehabilitation therapies. Since conducting the clinical trials needed for commercialization may be capital-intensive, the FOA aims to facilitate the transition of SBIR Phase II projects to the commercialization stage by promoting partnerships between NIH's SBIR/STTR awardees and third-party investors and/or strategic partners. Consistent with the goals of this funding initiative and as required by the SF424 instructions for all SBIR Phase II applications, applicants must submit a Commercialization Plan, which should include details on any independent third-party investor funding that has already been secured or is anticipated during the project period. It is expected that the level of this independent third-party funding will equal or exceed the NINDS funds being requested throughout the SBIR Phase IIB project period.

Notice NOT-TW-24-008 from the NIH Guide for Grants and Contracts

Notice NOT-DA-24-035 from the NIH Guide for Grants and Contracts